Last Updated on November 4, 2024 by The Health Master
Clinical Trial
Key Points:
- Intas Pharmaceutical has received approval from the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trial for its Ruxolitinib cream 1.5% w/w.
- The approval is subject to specific conditions, including the revision of the clinical trial protocol.
- The drug, Ruxolitinib, is a Janus kinase (JAK) inhibitor used to treat various blood disorders.
Intas Pharmaceutical has secured the green light from the CDSCO to initiate Phase III clinical trial for its innovative Ruxolitinib cream 1.5% w/w.
This pivotal development marks a significant step forward in the potential treatment of skin conditions.
The Road ahead
While the approval is a major milestone, Intas Pharmaceutical must adhere to specific conditions outlined by the CDSCO.
These conditions include:
- Revised Clinical Trial Protocol: The company must submit a revised clinical trial protocol that incorporates detailed information about the study centers where the trials will be conducted.
- Government Hospital Participation: A minimum of 50% of the study sites must be government hospitals.
- Age Criteria: The inclusion criteria for participants must be uniformly set at 18 years and above.
- Equivalence Study Documentation: The company must provide a comprehensive document detailing the rationale for the equivalence study and the specific study design.
Ruxolitinib: A Powerful Drug
Ruxolitinib, a potent Janus kinase (JAK) inhibitor, has demonstrated efficacy in treating various blood disorders.
By inhibiting the JAK1 and JAK2 protein kinases, Ruxolitinib disrupts specific cellular signaling pathways involved in disease progression.
Potential Benefits of Ruxolitinib Cream
The topical formulation of Ruxolitinib holds promise for the treatment of skin conditions.
While specific indications for the cream are yet to be fully determined, it is anticipated to offer relief for patients suffering from inflammatory skin disorders.
As Intas Pharmaceutical advances its Phase III clinical trial, the medical community eagerly awaits the potential benefits that Ruxolitinib cream may bring to patients.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Disclaimer: This content, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. The Health Master does not claim responsibility for this information.
CDSCO Gains Global Recognition: Milestone for Indian Medical Device Industry
CDSCO approval granted for Durvalumab therapy with specified indication
CDSCO Updates Guidance for Zonal, Sub-Zonal, and Port Offices
CDSCO to switch to online submission of Form 44
CDSCO must maintain a registry of all Brand Name of Drugs: Dr BR Jagashetty
No provision for separate license for Pharma marketers
Important short notes for Industry
Deadly reactor explosion at Pharma Plant in Andhra Pradesh
Drug recall: Dr Reddy’s recalls Cinacalcet Tablets due to impurity Concerns
Indian Pharma Industry to face New GMP Regulations Compliance
Clotrimazole Cream Price Dispute: Govt upholds NPPA’s Ceiling Price
Telangana DCA takes action on 15 Medical Stores for Violations
Govt to amend MDR to include QMS requirements for Class A Medical Devices
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
